Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report

Patients with relapsed or refractory non-Hodgkin lymphoma have a dismal prognosis. Chimeric Antigen Receptor (CAR)-modified T cells (CART cells) that targeted CD20 were effective in a phase I clinical trial for patients with advanced B-cell lymphomas. We performed a phase IIa trial to further assess...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wen-ying, Wang, Yao, Guo, Ye-lei, Dai, Han-ren, Yang, Qing-ming, Zhang, Ya-jing, Zhang, Yan, Chen, Mei-xia, Wang, Chun-meng, Feng, Kai-chao, Li, Su-xia, Liu, Yang, Shi, Feng-xia, Luo, Can, Han, Wei-dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661644/
https://www.ncbi.nlm.nih.gov/pubmed/29263894
http://dx.doi.org/10.1038/sigtrans.2016.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661644/
https://www.ncbi.nlm.nih.gov/pubmed/29263894
http://dx.doi.org/10.1038/sigtrans.2016.2

Ejemplares similares